Edwards Lifesciences
1,230 hedge funds and large institutions have $37.8B invested in Edwards Lifesciences in 2022 Q4 according to their latest regulatory filings, with 146 funds opening new positions, 397 increasing their positions, 475 reducing their positions, and 138 closing their positions.
41% more call options, than puts
Call options by funds: $180M | Put options by funds: $128M
6% more first-time investments, than exits
New positions opened: 146 | Existing positions closed: 138
3% more capital inflows, than outflows
Capital inflows: $3.44B | Capital outflows: $3.35B
0.08% more ownership
Funds ownership: 81.96% → 82.04% (+0.08%)
1% less funds holding
Funds holding: 1,247 → 1,230 (-17)
16% less repeat investments, than reductions
Existing positions increased: 397 | Existing positions reduced: 475
39% less funds holding in top 10
Funds holding in top 10: 18 → 11 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$363M |
| 2 |
D.E. Shaw & Co
New York
|
+$182M |
| 3 |
Millennium Management
New York
|
+$172M |
| 4 |
Two Sigma Advisers
New York
|
+$167M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$156M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$389M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$358M |
| 3 |
Janus Henderson Group
London,
|
-$275M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
-$223M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$95.4M |
EW Hedge Fund Activity: Q4 2022 in Review
1,230 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2022, worth a combined $37.8B — down 10% from $42B a quarter earlier.
Buyers outnumbered sellers: 146 funds opened new EW positions and 138 closed out — a net gain of 8 holders — while 397 added to existing stakes and 475 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $363M. The largest seller was Massachusetts Financial Services, exiting entirely with an estimated $389M sold.
- 1,230 institutional investors held Edwards Lifesciences (EW) as of Q4 2022, down from 1,247 in Q3 2022.
- Funds reported $37.8B of Edwards Lifesciences stock for Q4 2022, down 10% quarter-over-quarter.
- 146 funds opened new Edwards Lifesciences positions in Q4 2022 and 138 closed out, a net change of +8 holders.
- The largest Edwards Lifesciences buyer in Q4 2022 was AllianceBernstein, an estimated $363M added.
- The largest Edwards Lifesciences seller in Q4 2022 was Massachusetts Financial Services, an estimated $389M sold.
Based on aggregated 13F filings for Q4 2022.